Article | Published:

An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections

Nature Medicine volume 8, pages 13981404 (2002) | Download Citation

Subjects

Abstract

The role of host genetic factors in conferring predisposition or protection in infectious diseases has become evident. Infection with group A streptococci causes a wide spectrum of disease ranging from pharyngitis to streptococcal toxic shock syndrome. The release of inflammatory cytokines triggered by streptococcal superantigens has a pivotal role in invasive streptococcal disease. However, individuals infected with the same strain can develop very different manifestations. We report here that the immunogenetics of the host influence the outcome of invasive streptococcal infection, and demonstrate the underlying mechanism for these genetic associations. Specific human leukocyte antigen class II haplotypes conferred strong protection from severe systemic disease, whereas others increased the risk of severe disease. Patients with the DRB1*1501/DQB1*0602 haplotype mounted significantly reduced responses and were less likely to develop severe systemic disease (P < 0.0001). We propose that human leukocyte antigen class II allelic variation contributes to differences in severity of invasive streptococcal infections through their ability to regulate cytokine responses triggered by streptococcal superantigens.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , & The re-emergance of severe group A streptococcal disease: an evolutionary perspective. in Emerging Pathogens Vol. 7 (ASM Press, Washington, DC, 1998).

  2. 2.

    et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N. Engl. J. Med. 335, 547–554 (1996).

  3. 3.

    et al. Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity. Infect. Immun. 67, 1871–1877 (1999).

  4. 4.

    et al. Genetic relatedness and superantigen expression of M type 1 group A streptococcal isolates from severe and nonsevere invasive disease. Infect. Immun. 68, 3523–3534 (2000).

  5. 5.

    Bacterial exotoxins as superantigens. Clin. Microbiol. Rev. 8, 411–426 (1995).

  6. 6.

    et al. Selective depletion of V_-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. J. Infect. Dis. 171, 74–84 (1995).

  7. 7.

    et al. Evidence for superantigen involvement in severe group A streptococcal tissue infections. J. Infect. Dis. 184, 853–860 (2001).

  8. 8.

    et al. Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection. Eur. J. Immunol. 30, 3247–3255 (2000).

  9. 9.

    Genetics and genomics of infectious disease susceptibility. Br. Med. Bull. 55, 401–413 (1999).

  10. 10.

    , , , & HLA-DR alleles differ in their ability to present staphylococcal enterotoxins to T cells. J. Exp. Med. 172, 709–717 (1990).

  11. 11.

    , , , & Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am. J. Med. 103, 18–24 (1997).

  12. 12.

    & HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39, 2253 (1992).

  13. 13.

    et al. HLA class II associations with rheumatic heart disease are more evident and consistent among clinically homogeneous patients. Circulation 99, 2784–2790 (1999).

  14. 14.

    , , , & Caucasian Canadian normal. in HLA 1998 (ed. Gjertson, D.W. & Terasaki, P.I.) (American Society for Histocompatibility and Immunogenetics, Lenexa, 1998).

  15. 15.

    et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome—a comparative observational study. The Canadian Streptococcal Study Group. Clin. Infect. Dis. 28, 800–807 (1999).

  16. 16.

    et al. TNF microsatellites and streptococcal toxic shock syndrome. Hum. Immunol. 62 (Suppl. 1): S30 (2001).

  17. 17.

    , , & The serotypes of Streptococcus pyogenes present in Britain during 1980–1990 and their association with disease. J. Med. Microbiol. 39, 165–178 (1993).

  18. 18.

    , & Outbreak of group A streptococcal bacteremia in Sweden: an epidemiologic and clinical study. J. Infect. Dis. 164, 595–598 (1991).

  19. 19.

    & Streptococcal serogroup A epidemic in Norway 1987–1988. Scand. J. Infect. Dis. 22, 421–429 (1990).

  20. 20.

    et al. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective population–based study. JAMA 269, 384–389 (1993).

  21. 21.

    , & Differential induction of Th1 versus Th2 cytokines by group A streptococcal toxic shock syndrome isolates. Infect. Immun. 65, 5209–5215 (1997).

  22. 22.

    et al. Mutations in the MHC class II binding domains of staphylococcal enterotoxin A differentially affect T cell receptor V_ specificity. J. Immunol. 157, 3988–3994 (1996).

  23. 23.

    et al. CD28 cross-linking augments TCR-mediated signals and costimulates superantigen responses. J. Immunol. 154, 3180–3193 (1995).

Download references

Acknowledgements

We thank all infectious disease physicians in Canada who have contributed valuable samples and clinical information for this study; L. Trepski and the Ontario Streptococcal Study Group in Canada; and Y. Guédez of the Veterans Administration in Memphis. This work was supported by grants from the U.S. Veterans Administration Merit Award (M.K.), the National Institutes of Health (AI40198, M.K.) and the Swedish Medical Research Council (A.N.-T). The Ontario Streptococcal Study Group was originally started by funds from the Center for Disease Control.

Author information

Affiliations

  1. Veterans Affairs Medical Center, Research Service, Memphis, Tennessee, USA

    • Malak Kotb
    • , Anna Norrby-Teglund
    • , Hesham El-Sherbini
    • , M. Tevik Dorak
    • , Ayesha Khurshid
    •  & Jeanie Peeples
  2. Departments of Surgery and Molecular Sciences, University of Tennessee, Memphis, Tennessee, USA

    • Malak Kotb
    • , Hesham El-Sherbini
    • , M. Tevik Dorak
    • , Ayesha Khurshid
    •  & Jeanie Peeples
  3. Karolinska Institutet, Center for Infectious Medicine, Huddinge University Hospital, Stockholm, Sweden

    • Anna Norrby-Teglund
  4. Department of Microbiology, Mount Sinai Hospital, and the University of Toronto, Toronto, Canada

    • Allison McGeer
    • , Karen Green
    • , Judy Wade
    •  & Donald E. Low
  5. Department of Integrative Biology, University of California, Berkeley, California, USA

    • Glenys Thomson
  6. Centers for Disease Control and Prevention, Atlanta, Georgia, USA

    • Benjamin Schwartz

Authors

  1. Search for Malak Kotb in:

  2. Search for Anna Norrby-Teglund in:

  3. Search for Allison McGeer in:

  4. Search for Hesham El-Sherbini in:

  5. Search for M. Tevik Dorak in:

  6. Search for Ayesha Khurshid in:

  7. Search for Karen Green in:

  8. Search for Jeanie Peeples in:

  9. Search for Judy Wade in:

  10. Search for Glenys Thomson in:

  11. Search for Benjamin Schwartz in:

  12. Search for Donald E. Low in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Malak Kotb.

Supplementary information

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm1202-800

Further reading